XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma-Reference-Cited by-同舟云学术

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

Published:2016-10-28 Issue:48 Volume:7 Page:78896-78909
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Turner Joel G.¹,Kashyap Trinayan²,Dawson Jana L.¹,Gomez Juan¹,Bauer Alexis A.¹,Grant Steven³,Dai Yun³,Shain Kenneth H.¹⁴,Meads Mark¹,Landesman Yosef²,Sullivan Daniel M.¹⁵

Affiliation:

1. Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

2. Karyopharm Therapeutics, Natick, MA, USA

3. Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA

4. Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

5. Department of Blood & Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review;Cancer Drug Resistance;2024-06-26

2. Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis;Current Problems in Cancer;2024-06

3. A novel application of XPO1 inhibition for the treatment of myelofibrosis;Blood Neoplasia;2024-06

4. The nuclear export protein exportin‐1 in solid malignant tumours: From biology to clinical trials;Clinical and Translational Medicine;2024-05

5. Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the BOSTON trial;European Journal of Haematology;2024-05